APTX - Earnings announcements

Company expects to report results from Phase 2 study of NYX-458 in cognitive impairment in 1Q 2023 $5.6 million NIH grant finalized for research and development of NYX-783 in opioid use disorder $67 million cash balance provides operational runway into 2024 and enables readouts from multiple Phase 2 studies Management to host conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company's clinical-stage pipeline of novel NMDA receptor

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial 844-200-6205 (domestic) or 929-526-1599 (international) and refer to conference ID 141144. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx'

 Company expects to report results from Phase 2b study of NYX-2925 in fibromyalgia in August Data from Phase 2 study of NYX-458 in cognitive impairment expected in 1Q 2023 IND cleared for NIH grant-funded evaluation of NYX-783 in opioid use disorder $85 million cash balance provides operational runway into 2024 and enables readouts from multiple Phase 2 studies Management to host conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2022 and provided key business updates across the

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial (888) 660-6390 (domestic) or (929) 203-1902 (international) and refer to conference ID 4855909. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Apt

Current cash position of > $100 million expected to fund operations into 2024 and enable readouts from all three ongoing Phase 2 studies Data readout from Phase 2b study of NYX-2925 in fibromyalgia expected in early to mid 3Q 2022 Data readout from exploratory Phase 2 study of NYX-458 in cognitive impairment expected in late 2022 or 1Q 2023 Data readout from Phase 2b study of NYX-783 50 mg in PTSD expected in 2H 2023 Conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the first quarter of 2022 and highlighted re

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, May 12, 2022 at 5:00 p.m. ET to report first quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial (844) 200-6205 (domestic) or (929) 526-1599 (international) and refer to conference ID 305649. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx

Data readouts from Phase 2b studies of NYX-2925 in painful DPN and fibromyalgia expected in April 2022 and early to mid 3Q 2022, respectively Ongoing Phase 2 study in cognitive impairment expected to read out in late 2022 or 1Q 2023 Initiated Phase 2b study of NYX-783 50 mg in PTSD in 4Q 2021; Phase 2b study of NYX-783 150 mg in PTSD expected to commence in early 2Q 2022 Balance sheet expected to fund R&D and operations through mid 2023 Conference call today at 5:00 p.m. EDT Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the fourth qu

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesday, March 23, 2022 at 5:00 p.m. ET to report fourth quarter and full year 2021 financial results and discuss recent business highlights. To access the live conference call, please dial (844) 200-6205 (domestic) or (929) 526-1599 (international) and refer to conference ID 768426. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be a

Completed enrollment in Phase 2b study of NYX-2925 in patients with painful diabetic peripheral neuropathy; results expected in early to mid 2Q 2022 Phase 2b fibromyalgia study and exploratory Phase 2 cognitive impairment study remain on track for readouts in 2022 PTSD Phase 2b program is set to initiate in 4Q 2021 Strong balance sheet supports Phase 2 data readouts from all four clinical development programs Management to host conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 20

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 9, 2021 at 5:00 p.m. ET to report third quarter 2021 financial results and discuss recent business highlights. To access the live conference call, please dial (844) 200 6205 (domestic) or (929) 526 1599 (international) and refer to conference ID 322632. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Apti

Enrollment on track in both Phase 2b chronic pain studies with NYX-2925—data readouts expected 1H 2022 Enrollment on track in Phase 2 cognitive impairment study with NYX-458—data readout expected 2H 2022 Completed FDA meeting on NYX-783 development—expect to initiate Phase 2b studies in PTSD in 4Q 2021 and 1Q 2022 Initiating CEO transition plan—effective January 1, 2022, Aptinyx CEO Norbert Riedel will assume role of executive chairperson and be succeeded by president and COO, Andy Kidd Conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today repo

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, August 10, 2021 at 5:00 p.m. ET to report second quarter 2021 financial results and discuss recent business highlights. To access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-2205 (international) and refer to conference ID 2576236. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx's web